bluebird bio, Inc. (BLUE)
After hours:
| Previous close | 0.4947 |
| Open | 0.4895 |
| Bid | 0.3514 x 200 |
| Ask | 0.6424 x 200 |
| Day's range | 0.4895 - 0.5100 |
| 52-week range | 0.4500 - 5.5300 |
| Volume | |
| Avg. volume | 7,592,153 |
| Market cap | 98.12M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOMERVILLE, Mass., October 04, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement awards of 242,500 restricted stock units (RSUs). This includes the previously disclosed 100,000 RSUs granted to the Company’s CFO, James Sterling, with a grant date of September 30, 2024 and 142,500 RSUs granted to 19 other employees, with a grant date of October 1, 2024 (collectively, the "Inducement Grants").
- Business Wire
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
SOMERVILLE, Mass., September 27, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the "Q2 2024 Form 10-Q") with the Securities and Exchange Commission ("SEC").
- Business Wire
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
SOMERVILLE, Mass., September 24, 2024--Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduct
